%PDF-1.4
%
56 0 obj
<>
endobj
53 0 obj
<>
endobj
121 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T19:28:20Z
2024-03-28T10:10:14-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T10:10:14-07:00
application/pdf
Heather
2002-240.nov
uuid:6f94de4f-1dd2-11b2-0a00-770927fd5800
uuid:6f94de52-1dd2-11b2-0a00-6a0000000000
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
57 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
147 0 obj
[152 0 R]
endobj
148 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
109.22 59.09 396.48 -10.84 re
f*
0 0 0 1 K
0.5 w
109.22 59.09 396.48 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5294 Tm
[(17.)-875 (Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout.)]TJ
0 Tc 2.175 -1.25 Td
(Ann Rheum Dis 1997;56:696-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875 (Schlesinger N, Baker DG, Schumacher HR Jr)55 (. Serum urate during)]TJ
2.175 -1.25 Td
(bouts of acute gouty arthritis. J Rheumatol 1997;24:2265-6.)Tj
-2.175 -1.25 Td
[(19.)-875 (T)70 (omita M, Mizuno S, )37 (Y)100 (amanaka H, et al. Does hyperuricemia)]TJ
2.175 -1.25 Td
[(af)18 (fect mortality? )55 (A)-220 (prospective cohort study of Japanese male)]TJ
0 -1.25 TD
(workers. J Epidemiol 2000;10:403-9.)Tj
-2.175 -1.25 Td
[(20.)-875 (Bickel C, Rupprecht HJ, Blankenber)18 (g S, et al. Serum uric acid as)]TJ
2.175 -1.25 Td
(an independent predictor of mortality in patients with )Tj
T*
[(angiographically proven coronary artery disease. )55 (Am J Cardiol)]TJ
0 Tc 0 Tw T*
(2002;89:12-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875 (W)80 (ong KY)129 (, Macwalter RS, Fraser HW)92 (, Crombie I, Ogston SA,)]TJ
2.175 -1.25 Td
[(Struthers )55 (AD. Urate predicts subsequent cardiac death in stroke)]TJ
T*
(survivors. Eur Heart J 2002;23:788-93.)Tj
-2.175 -1.25 Td
[(22.)-875 (Perez-Ruiz F)80 (, Calabozo M, Herrero-Beites )55 (AM, Garcia-Erauskin G,)]TJ
2.175 -1.25 Td
(Pijoan JI. Improvement of renal function in patients with chronic)Tj
T*
(gout after proper control of hyperuricemia and gouty bouts.)Tj
0 Tc T*
(Nephron 2000;86:287-91.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875 (van Lieshout-Zuidema MF)80 (, Breedveld FC. )18 (W)40 (ithdrawal of long-term)]TJ
2.175 -1.25 Td
(antihyperuricemic therapy in tophaceous gout. J Rheumatol)Tj
0 Tc 0 Tw T*
(1993;20:1383-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875 (Bull PW)92 (, Scott JT)74 (. Intermittent control of hyperuricemia in the)]TJ
2.175 -1.25 Td
(treatment of gout. J Rheumatol 1989;16:1246-8.)Tj
-2.175 -1.25 Td
[(25.)-875 (Chou CT)74 (, Kuo SC. )18 (The anti-inflammatory and anti-hyperuricemic)]TJ
2.175 -1.25 Td
[(ef)18 (fects of Chinese herbal formula danggui-nian-tong-tang on acute)]TJ
T*
(gouty arthritis: a comparative study with indomethacin and )Tj
0 Tc T*
[(allopurinol. )55 (Am J Chin Med 1995;23:261-71.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875 (Darmawan J, )18 (V)111 (alkenbur)18 (g HA, Muirden KD, )18 (W)40 (igley RD.)]TJ
2.175 -1.25 Td
(Epidemiology of rheumatic diseases in rural and urban populations)Tj
33 35 Td
[(in Indonesia: a )18 (W)80 (orld Health Or)18 (ganization\320International League)]TJ
T*
[(Against Rheumatism COPCORD study)65 (, stage I, phase 2. )55 (Ann)]TJ
T*
(Rheum Dis 1992;51:525-8.)Tj
-2.175 -1.25 Td
[(27.)-875 (Petri M, Spence D, Bone LR, Hochber)18 (g MC. Coronary artery)]TJ
2.175 -1.25 Td
(disease risk factors in the Johns Hopkins Lupus Cohort: prevalence,)Tj
T*
(recognition by patients, and preventive practices. Medicine)Tj
T*
(Baltimore 1992;71:291-302.)Tj
-2.175 -1.25 Td
[(28.)-875 (Darmawan J, )18 (V)111 (alkenbur)18 (g HA, Muirden KD, )18 (W)40 (igley RD. )55 (Arthritis)]TJ
2.175 -1.25 Td
(community education by leather puppet \(wayang kulit\) shadow)Tj
T*
(play in rural Indonesia \(Java\). Rheumatol Int 1992;12:97-101.)Tj
-2.175 -1.25 Td
[(29.)-875 (W)80 (erlen D, Gabay C, )18 (V)60 (ischer )18 (TL. Corticosteroid therapy for the)]TJ
2.175 -1.25 Td
[(treatment of acute attacks of crystal-induced arthritis: an ef)18 (fective)]TJ
T*
(alternative to nonsteroidal antiinflammatory drugs. Rev Rheum)Tj
0 Tc T*
(Engl Ed 1996;63:248-54.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875 (Rosenthal )55 (AK, R)40 (yan LM. )18 (T)35 (reatment of refractory crystal-associated)]TJ
2.175 -1.25 Td
[(arthritis. Rheum Dis Clin North )55 (Am 1995;1:151-61.)]TJ
-2.175 -1.25 Td
[(31.)-875 (Emkey RD, Lindsay R, L)55 (yssy J, )18 (W)80 (eisber)18 (g JS, Dempster DW)92 (, Shen)]TJ
2.175 -1.25 Td
[(V)129 (. )18 (The systemic ef)18 (fect of intraarticular administration of )]TJ
T*
(corticosteroid on markers of bone formation and bone resorption in)Tj
T*
[(patients with rheumatoid arthritis. )55 (Arthritis Rheum 1996;39:277-82.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Gray RG, )18 (T)70 (enenbaum J, Gottlieb NL. Local corticosteroid )]TJ
2.175 -1.25 Td
[(treatment in rheumatic disorders. Semin )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1981;10:231-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875 (Levy FL, )55 (Adams-Huet B, Pak CYC. )55 (Ambulatory evaluation of)]TJ
2.175 -1.25 Td
[(nephrolithiasis: update of a 1980 protocol. )55 (Am J Med )]TJ
0 Tc 0 Tw T*
(1995;98:50-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875 (Darmawan J. Rheumatic conditions in the northern part of Central)]TJ
2.175 -1.25 Td
[(Java. )55 (An epidemiological survey [PhD thesis]. Rotterdam: Erasmus)]TJ
T*
(University; 1988, 178 p.)Tj
ET
0 0 0 0 k
408 770 150 -25 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 20.37 0 0 21 461.9631 753.6089 Tm
(\002\003\003\002\004\002\005\003\004\()Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Darmawan, et al: Contr)37 (ol of chr)37 (onic gout)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2443)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
36 0 obj
<>stream
8;Z\7>EZlX#ikn#j>rik/KqllAfLKB-o7D>`Y])7;tn3KB'*-Cm/^RL+8ajDDrVu0
0/&U>asUO3S)Xqj=71H*4GI[;)(XR\,hrlL=Y]&EnJJ\N924Dt4_A+D6?+XBF_n+i
C+2!0F=YqT7#8jI:#%`gEq*_#4'ZZNSAuu"cI9*@*;H24\.EFObqr
d\uV;pCcbZJ5AfSaT4dmb^1L&fO#Qm8C_ZmJ((r1!F85A9+!Y8(F.nRK9`d%deZD6>qBSSF(
;F=?)/cJ/mfhO[581e%=(dASGdJsr;6m@aa,SGr%,4RAR4s"]aiUNo'e`aZKEbhNL
Vu&]k"oqY/QY6~>
endstream
endobj
40 0 obj
[/Indexed/DeviceRGB 255 39 0 R]
endobj
39 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
68 0 obj
<>
endobj
61 0 obj
<>
endobj
63 0 obj
<>
endobj
98 0 obj
<>
endobj
126 0 obj
<>
endobj
60 0 obj
<>
endobj
91 0 obj
<>stream
HUiPSY~K, y:n]JĥimEADAlA"D$, d3d
#
[۶أNuUy,ў?SNWιߩ]stpwX? xvD&VWFK%>?g녳Xo""0GY!@_rIf_ſ!G
/AF8Urwwjy*Edf9pG\¬LjB)))Ih8V0R#W4{ČDD3ʔX,:%f%r*I̬ZD'Ε0;OJS$bx/nl<cð=?W=|Xxѱ{guҩn
9IY:mF;/wvϸ~/:~ ˜yΕ].sm[7.t/s>1~?W *pĿK@.}[N5-5h*K2B.TdjTAAc-`QFHq[R,T\*Zmx}8{6/:\TrOFjK\2^h>{#p_pNYGuӗ/}e8T9''GjtA]eҹʧ~mt0 dK&1-
E9l!bFu֬A1ŇMe*G8`TZ Ro7(h¢T`퍤k,NmAFudlYyLfdFGL74o)h,.NcۤXEADe "brɗd
OȍWI,TW{OencN:ye7MÖa#fX~QO$7ҊtU:SŇإf.%Xm=*]LUb$0r@k|éL8@$
Q*K`/UhThvmк՚$}x"ojyݚ=S?0ZX
hry@[Y#lhJ:oS~??<晩?8;wFŪOT\*+EfSU+
mmhRPX]*JNoL{5 C׆aяkr Y&w`?W8MPr7ټ]m%wFR#WU}ѷ͚Y]2BZs5ܸ~meSq=뚎]\E µVXUz,.E}vddI3yk{
o})9_ދtX[zDZM)Y+>jnU*\Oa|ΤI{"ܷAFk#ciVc0䎦 p
2l衃g]O-@y"IN^zv+rG4)!^<\^wn haE<m~A>s;ch%l:/>63&Y)?5fnt*O?)-HZɺ[ Ja,(?
֖#B[_l?ZMMa'^S!? zZ